NEW YORK (GenomeWeb News) – Life Technologies said today that Zymera has licensed its quantum dot intellectual property portfolio.
Zymera plans to use the Qdot nanocrystals to create self-illuminating quantum dot products that will be used in in vivo imaging, biomarker discovery, and in biosensing applications. Zymera's self-illumination technology uses bioluminescence resonance energy transfer, to transfer light from bioluminescent proteins, such as luciferase, onto quantum dots.
The Qdot nanocrystals, which emit bright light when exposed to ultraviolet light, are used in disease studies and for detecting targets in complex mixtures.
Financial terms of the agreement were not released.